PDCD1 and non-small cell lung carcinoma: The authors showed a high bTMB value of ≥ 6, which is related to long progression-free survival, suggesting that bTMB may be a promising biomarker to predict clinical benefit for advanced NSCLC patients to anti-PD-1 and anti-PD-L1 therapies (78).